#Coronavirus Disease Research #References (by AMEDEO, May 10 '25)

 

Antiviral Res

1. MARTIN HJ, Hossain MA, Wellnitz J, Kelestemur E, et al
   Chemical arsenal for helicase Hunters: Striking the toughest targets in antiviral research.
   Antiviral Res. 2025;239:106184.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

2. BANHOLZER N, Middelkoop K, Schmutz R, Leukes J, et al
   Infection prevention and control measures during the COVID-19 pandemic and airborne tuberculosis transmission during primary care visits in South Africa.
   Int J Infect Dis. 2025 May 6:107921. doi: 10.1016/j.ijid.2025.107921.
   PubMed         Abstract available
   
   

   
   J Infect

3. RIEDMANN U, Chalupka A, Richter L, Werber D, et al
   Underlying health biases in previously-infected SARS-CoV-2 vaccination recipients: a cohort study.
   J Infect. 2025 Apr 30:106497. doi: 10.1016/j.jinf.2025.106497.
   PubMed         Abstract available
   
   

   
   J Med Virol

4. MAZZOTTA V, Lepri AC, Del Borgo C, Lanini S, et al
   Comparative Analysis of Early COVID-19 Treatment Efficacy in a Multicentric Regional Cohort in Italy: Emulation of a Series of Target Trials.
   J Med Virol. 2025;97:e70379.
   PubMed         Abstract available
   
   
5. CENAT JM, Moshirian Farahi SMM, Dalexis RD, Muray M, et al
   COVID-19 Vaccine Uptake Rates and Associated Factors in Racially Diverse Parents in Canada: The Threat From Conspiracy Beliefs and Racial Discrimination.
   J Med Virol. 2025;97:e70376.
   PubMed         Abstract available
   
   
6. SANCHEZ-SIMARRO A, Panizo N, Gimenez E, Albert E, et al
   Dynamics of SARS-CoV-2 Spike Receptor-Binding Domain-Targeted Specific Peripheral Memory B Cells in Patients With End-Stage Chronic Kidney Disease Undergoing Replacement Therapy Following COVID-19 Vaccination.
   J Med Virol. 2025;97:e70382.
   PubMed         Abstract available
   
   
7. YANG H, Gao L, Xue Y, Zhang Z, et al
   Clinical Characteristics and Treatment Efficacy in Patients With SARS-CoV-2 Positivity After Nirmatrelvir-Ritonavir Therapy.
   J Med Virol. 2025;97:e70377.
   PubMed         Abstract available
   
   
8. ZHANG R, Li D, Gao P, Ruan W, et al
   A SARS-CoV and SARS-CoV-2 RBD Heterodimer Vaccine Candidate.
   J Med Virol. 2025;97:e70367.
   PubMed         Abstract available
   
   

   
   J Virol

9. DAI J, Feng Y, Long H, Liao Y, et al
   Dexamethasone disrupts intracellular pH homeostasis to delay coronavirus infectious bronchitis virus cell entry via sodium hydrogen exchanger 3 activation.
   J Virol. 2025 May 9:e0189424. doi: 10.1128/jvi.01894.
   PubMed         Abstract available
   
   
10. LUGANO D, Mwangi K, Mware B, Kibet G, et al
    Characterization of SARS-CoV-2 intrahost genetic evolution in vaccinated and non-vaccinated patients from the Kenyan population.
    J Virol. 2025 May 6:e0048225. doi: 10.1128/jvi.00482.
    PubMed         Abstract available
    
    

    
    JAMA

11. RUDMAN SPERGEL AK, Wu I, Deng W, Cardona J, et al
    Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine in Adults >/=50 Years: A Randomized Clinical Trial.
    JAMA. 2025 May 7:e255646. doi: 10.1001/jama.2025.5646.
    PubMed         Abstract available
    
    

    
    Nature

12. MALLAPATY S
    Trump freezes 'gain of function' pathogen research - threatening all US virology, critics say.
    Nature. 2025 May 7. doi: 10.1038/d41586-025-01411.
    PubMed        
    
    
13. KIYONO H, Ernst PB
    Nasal vaccines for respiratory infections.
    Nature. 2025;641:321-330.
    PubMed         Abstract available